Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques-Reference-Cited by-同舟云学术

Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques

Published:2024-04-26 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Kaiser Jaclyn A.,Nelson Christine E.^ORCID,Liu Xueqiao,Park Hong-Su^ORCID,Matsuoka Yumiko,Luongo Cindy^ORCID,Santos Celia,Ahlers Laura R. H.,Herbert Richard,Moore Ian N.,Wilder-Kofie Temeri,Moore Rashida,Walker April,Yang Lijuan,Munir Shirin^ORCID,Teng I-Ting,Kwong Peter D.^ORCID,Dowdell Kennichi^ORCID,Nguyen Hanh^ORCID,Kim JungHyun,Cohen Jeffrey I.,Johnson Reed F.,Garza Nicole L.,Via Laura E.^ORCID,Barber Daniel L.^ORCID,Buchholz Ursula J.^ORCID,Le Nouën Cyril^ORCID

Abstract

AbstractImmunization via the respiratory route is predicted to increase the effectiveness of a SARS-CoV-2 vaccine. Here, we evaluate the immunogenicity and protective efficacy of one or two doses of a live-attenuated murine pneumonia virus vector expressing SARS-CoV-2 prefusion-stabilized spike protein (MPV/S-2P), delivered intranasally/intratracheally to male rhesus macaques. A single dose of MPV/S-2P is highly immunogenic, and a second dose increases the magnitude and breadth of the mucosal and systemic anti-S antibody responses and increases levels of dimeric anti-S IgA in the airways. MPV/S-2P also induces S-specific CD4+ and CD8+ T-cells in the airways that differentiate into large populations of tissue-resident memory cells within a month after the boost. One dose induces substantial protection against SARS-CoV-2 challenge, and two doses of MPV/S-2P are fully protective against SARS-CoV-2 challenge virus replication in the airways. A prime/boost immunization with a mucosally-administered live-attenuated MPV vector could thus be highly effective in preventing SARS-CoV-2 infection and replication.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Vaccine Research Center, NIAID, NIH

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-47784-6.pdf

Reference41 articles.

1. WHO. COVID-19 epidemiological update. in Emergency Situational Updates 164 edn (World Health Organization, 2024).

2. Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31, 146–157 (2023).

3. Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N. & Bull, R. A. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev. Med. Virol. 32, e2381 (2022).

4. Brock, L. G. et al. Murine pneumonia virus expressing the fusion glycoprotein of human respiratory syncytial virus from an added gene is highly attenuated and immunogenic in rhesus macaques. J. Virol. 92, e00723–18 (2018).

5. Brock, L. G., Karron, R. A., Krempl, C. D., Collins, P. L. & Buchholz, U. J. Evaluation of pneumonia virus of mice as a possible human pathogen. J. Virol. 86, 5829–5843 (2012).